Premium
Severe Hepatocellular Dysfunction following Cyproterone Acetate Therapy
Author(s) -
PARYS B. T.,
HAMID S.,
THOMSON R. G. N.
Publication year - 1991
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1991.tb15142.x
Subject(s) - cyproterone acetate , medicine , hepatocellular carcinoma , cyproterone , toxicity , complication , fulminant hepatitis , gastroenterology , toxic hepatitis , fulminant , hepatitis , surgery , androgen , hormone
Summary— Cyproterone acetate (CPA) is a widely used drug in the treatment of advanced prostatic carcinoma. Although it is generally well tolerated, liver toxicity has been recognised as a complication of long‐term use. We report 3 patients with severe hepatocellular damage due to CPA therapy, 2 with fatal fulminant hepatitis.